EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Approach to thyroid disorders associated with immune checkpoint inhibitors and tyrosine kinase inhibitors

Vaishali Padhye, Jui Ho iD

Internal Medicine Journal · 2026-07 · 56 (7) · 1258-1262

DOI: 10.1111/imj.70507 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Internal Medicine Journal, online erschienen am 26.06.2026. Verfasst von Vaishali Padhye und 1 weiteren Autor:innen. Beteiligte Einrichtung: Southern Adelaide Diabetes and Endocrine Services, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Thyroid Diseases, Protein Kinase Inhibitors. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have revolutionised the therapeutic landscape for a range of malignancies. However, their use is frequently associated with immune‐related adverse events (irAEs), particularly affecting the endocrine system. Thyroid dysfunction is the most common endocrine irAE, often occurring without symptoms, making routine thyroid function monitoring critical for early detection. Hypothyroidism is the predominant manifestation, though hyperthyroidism and central hypothyroidism due to immune‐mediated hypophysitis are also observed. Subclinical hypothyroidism may be monitored in the absence of symptoms; however, early treatment with cautious levothyroxine initiation is advised in patients with pre‐existing cardiac disease. When central hypothyroidism is suspected, adrenal insufficiency must be excluded before starting thyroid hormone therapy, and glucocorticoid replacement should precede levothyroxine to avoid precipitating an adrenal crisis. In cases of hyperthyroidism, transient thyroiditis and Graves disease should be considered. Persistent hyperthyroidism warrants further evaluation with thyroid receptor antibodies or a radionuclide thyroid scan. Management of endocrine irAEs depends on the severity (toxicity grade). Immunotherapy may be continued in mild cases but should be withheld temporarily in moderate to severe presentations. A multidisciplinary approach, particularly involving oncologists and endocrinologists, is essential to ensure optimal care and improve long‐term outcomes for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsThyroid DiseasesProtein Kinase InhibitorsHumansTyrosine Kinase InhibitorsNeoplasms

Stichwörter der Autor:innen

immune checkpoint inhibitorthyroid disordertyrosine kinase inhibitor

Substanzen

Immune Checkpoint InhibitorsProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Southern Adelaide Diabetes and Endocrine Services, Adelaide, South Australia, Australia.

ORCID-Profile: Jui Ho

Zitieren

APA

Padhye, V., & Ho, J. (2026). Approach to thyroid disorders associated with immune checkpoint inhibitors and tyrosine kinase inhibitors. Internal Medicine Journal, 56(7), 1258-1262. https://doi.org/10.1111/imj.70507

Vancouver

Padhye V, Ho J. Approach to thyroid disorders associated with immune checkpoint inhibitors and tyrosine kinase inhibitors. Internal Medicine Journal. 2026;56(7):1258-1262. doi:10.1111/imj.70507

BibTeX
@article{Padhye2026,
  author = {Padhye, Vaishali and Ho, Jui},
  title = {Approach to thyroid disorders associated with immune checkpoint inhibitors and tyrosine kinase inhibitors},
  journal = {Internal Medicine Journal},
  year = {2026},
  volume = {56},
  number = {7},
  pages = {1258--1262},
  doi = {10.1111/imj.70507}
}
Kostenlos starten →